ATF4 and cancer: Furthermore, the modest activation of ATF4 in Rv‐treated cancer cells is consistent with lack of detectable activation of PKR and GCN2 since ATF4 is an important effector of the ISR (Pakos‐Zebrucka et al, 2016).